Clinical trial
A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
NCT00780663 is registered in ClinicalTrials.gov with Cylene Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Multi-Center, Open Label Study Evaluating the Efficacy and Safety of Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
- Lead sponsor
- Cylene Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 31, 2008
- Completion date
- March 31, 2010
- Enrollment
- 25 (estimated)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.